公开(公告)号：US20230218518A1

公开(公告)日：2023-07-13

申请号：US18150152

申请日：2023-01-04

申请人： The Regents of the University of California

发明人： Seema S. Aceves ,  Ranjan Dohil ,  Quan Nhu

IPC分类号： A61K9/00 ,  A61K31/426 ,  A61K47/32 ,  A61K9/20 ,  A61K31/573 ,  A61K9/48 ,  A61K47/38

CPC分类号： A61K9/0095 ,  A61K31/426 ,  A61K47/32 ,  A61K9/20 ,  A61K31/573 ,  A61K9/4808 ,  A61K47/38

摘要： The disclosure relates to methods and compositions to treat an eosinophilic disease or disorder. More particularly, the disclosure provides methods and compositions for treating eosinophilic esophagitis.

公开(公告)号：US11690789B2

公开(公告)日：2023-07-04

申请号：US16468844

申请日：2017-12-22

申请人： R.P. Scherer Technologies, LLC

发明人： Shawn P. McKee ,  David G. Williams, Sr. ,  Lester David Fulper

IPC分类号： A61J3/07 ,  A61K9/48

CPC分类号： A61J3/07 ,  A61K9/4808

摘要： The invention provides a die suitable for producing a multi-chamber softgel capsule. The die comprises a die pocket defined by a die pocket wall and a bottom surface. The die comprises one or more partitioning walls dividing the die pocket into two or more chambers The top of the land of the partitioning walls have a lowest point that is lower than the plane formed by the top of the land along the perimeter of the die pocket wall by a gap. A die roll comprising a plurality of the dies is also provided, as well as rotary-die encapsulation machine comprising the die roll.

公开(公告)号：US20230190794A1

公开(公告)日：2023-06-22

申请号：US18169061

申请日：2023-02-14

申请人： LPOXY THERAPEUTICS, INC

发明人： Larry D. Sutton

IPC分类号： A61K33/40 ,  A61K9/00 ,  A61K9/20 ,  C12N9/08 ,  A61K9/48

CPC分类号： A61K33/40 ,  A61K9/0053 ,  A61K9/20 ,  C12N9/0065 ,  A61K9/4808 ,  C12Y111/01006

摘要： Agents, kits, and methods that utilize oxygenation to treat Inflammatory Bowel Disease (IBD) and/or provide prophylaxis against exacerbation of IBD are provided. In several embodiments, the agents, kits, and methods according to several embodiments generate in, or carry to, oxygen in the intestinal lumen to treat IBD and provide prophylaxis against exacerbation of IBD, including those caused by the presence of anaerobic bacteria in the intestine. The agents, kits, and methods provided herein generate an aerobic environment within the intestine to alleviate intestinal inflammation.

公开(公告)号：US20230149365A1

公开(公告)日：2023-05-18

申请号：US17863754

申请日：2022-07-13

申请人： Nuray Chemicals Private Limited

发明人： Muthusamy SHANMUGAM ,  Ramasamy VENKATRAGAVAN ,  Singavarapu Ajay MADHUKAR ,  Erugu BALAIAH ,  Palanisamy SIVAKUMAR ,  Thirunavukkarasu SAKTHIKUMAR

IPC分类号： A61K31/423 ,  A61K9/48 ,  A61K47/12 ,  A61K47/38 ,  A61K47/42 ,  A61K47/26 ,  A61K47/40

CPC分类号： A61K31/423 ,  A61K9/4808 ,  A61K47/12 ,  A61K47/38 ,  A61K47/42 ,  A61K47/26 ,  A61K47/40

摘要： The disclosure relates to a novel dosage form comprising hard gelatin or HPMC capsule having granule composition, spray dried or evaporated composition comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine or solid-state forms or polymorphic forms of tafamidis particularly tafamidis free acid fumaric acid cocrystal and tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine or solid-state forms or polymorphic forms of tafamidis particularly tafamidis free acid fumaric acid cocrystal that would not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and that composition is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

公开(公告)号：US20230149315A1

公开(公告)日：2023-05-18

申请号：US17784453

申请日：2020-12-11

申请人： Jeffrey SHIMIZU ,  Mitchell Lawrence JONES ,  Mark Sasha DRLIK ,  Iman NIKNIA ,  Nathan John MULLER ,  Tuyen NGUYEN ,  Christopher Loren WAHL ,  Edward MUDGE ,  Nicholas Mark SALT ,  Nia Eleri STEVENS ,  Stuart Robert ABERCROMBIE ,  Christophel Ian BUNCE ,  Ryan Elliott JONES ,  PROGENITY, INC.

发明人： Jeffrey A. SHIMIZU ,  Mitchell Lawrence JONES ,  Mark Sasha DRLIK ,  Iman NIKNIA ,  Nathan John MULLER ,  Tuyen NGUYEN ,  Christopher Loren WAHL ,  Edward MUDGE ,  Nicholas Mark SALT ,  Nia Eleri STEVENS ,  Stuart Robert ABERCROMBIE ,  Christopher Ian BUNCE ,  Ryan Elliott JONES ,  Kevin David HOWE ,  Pejman RAHIMIAN ,  Nelson QUINTANA

IPC分类号： A61K9/48 ,  A61M31/00 ,  A61M37/00

CPC分类号： A61K9/4808 ,  A61M31/002 ,  A61M37/0015 ,  A61M2210/1042 ,  A61M2037/0061

摘要： Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

公开(公告)号：US20190216685A1

公开(公告)日：2019-07-18

申请号：US16362475

申请日：2019-03-22

申请人： BARLEAN'S ORGANIC OILS, LLC

发明人： John PUCKETT

IPC分类号： A61J3/07 ,  A61K31/201 ,  A61K31/202 ,  A61K9/48 ,  A61K31/00

CPC分类号： A61J3/07 ,  A61K9/4808 ,  A61K9/4825 ,  A61K9/4833 ,  A61K31/00 ,  A61K31/201 ,  A61K31/202 ,  B29C43/08 ,  B29C43/085 ,  B29C2043/3678 ,  B30B11/165

摘要： Provided is a die roll for manufacturing softgels, a softgel, and methods for producing a softgel. The die roll includes a die roll surface and a pocket defined therein. The pocket includes a floor, an interior sidewall surface, a chamfer, and an exterior sidewall surface. The floor is recessed relative to the die roll surface and the interior sidewall surface is connected to the floor and extends above the die roll surface to the chamfer. The pocket also includes a landing surface that is elevated from the die role surface and connects the chamfer to the exterior sidewall surface of the pocket. The landing surface includes a taper (such that the landing surface tapers inwardly towards the pocket floor) and a radius (such that the landing surface is not flat). Also provided is a softgel having a trailing edge thickness that is at least about 40% the thickness of the softgel wall thickness.

公开(公告)号：US20190209480A1

公开(公告)日：2019-07-11

申请号：US16360865

申请日：2019-03-21

申请人： INSPIRION DELIVERY SCIENCES LLC

发明人： Manish S. SHAH ,  Ray J. DIFALCO

IPC分类号： A61K9/20 ,  A61K31/4458 ,  A61K31/437 ,  A61K31/138 ,  A61K9/48 ,  A61K9/16 ,  A61K31/485 ,  A61K9/28 ,  A61K9/24 ,  A61K9/50 ,  A61K47/38 ,  A61K47/32 ,  A61K47/34

CPC分类号： A61K9/2086 ,  A61K9/16 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2081 ,  A61K9/209 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2886 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4891 ,  A61K9/5026 ,  A61K9/5031 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5078 ,  A61K31/138 ,  A61K31/437 ,  A61K31/4458 ,  A61K31/485 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  Y10T156/10

摘要： An oral pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in a monolithic dosage form, wherein the dosage form is configured such that when the dosage form is divided into more than one piece and at least one of the pieces is administered to a subject the Cmax, AUC, and/or rate of drug released after administration is substantially the same or lower and the Tmax is higher than the Cmax, AUC, rate of drug released, and/or Tmax after administration of: (1) a comparable composition in intact dosage form of equal drug dosage of the administered at least one piece; (2) a bioequiva lent drug composition in an intact dosage form of equal drug dosage to the administered at least one piece; and (3) a divided piece of a bioequivalent drug composition, wherein the divided piece comprises a drug dosage equal to the dosage of the administered piece of the oral composition. Methods of making the same and methods of using the same are also provided.

公开(公告)号：US20190184144A1

公开(公告)日：2019-06-20

申请号：US16011457

申请日：2018-06-18

申请人： Rani Therapeutics, LLC

发明人： Mir Imran

IPC分类号： A61M31/00 ,  A61K31/155 ,  A61K38/28 ,  A61K9/48 ,  A61K38/26 ,  A61M25/10 ,  A61M5/00 ,  A61M37/00 ,  A61K45/06 ,  A61K9/00

CPC分类号： A61M31/002 ,  A61K9/0053 ,  A61K9/4808 ,  A61K31/155 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61M5/00 ,  A61M25/10 ,  A61M25/10185 ,  A61M37/0015 ,  A61M2037/0023

摘要： Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

公开(公告)号：US20190117599A1

公开(公告)日：2019-04-25

申请号：US16172208

申请日：2018-10-26

申请人： LAURENT PHARMACEUTICALS

发明人： Aimesther BETANCOURT ,  Marc LEMIEUX ,  Roch THIBERT

IPC分类号： A61K31/167 ,  A61K9/20 ,  A61K9/48

CPC分类号： A61K31/167 ,  A61K9/146 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2095 ,  A61K9/4808 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/5084

摘要： Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration.

公开(公告)号：US20190029965A1

公开(公告)日：2019-01-31

申请号：US16151253

申请日：2018-10-03

申请人： Capsugel Belgium NV

发明人： Chang Q. Lee ,  Hassan Benameur

IPC分类号： A61K9/48 ,  A61K31/4439

CPC分类号： A61K9/4808 ,  A61K9/4816 ,  A61K31/4439

摘要： The present disclosure relates to delivery systems and methods for increasing the bioavailability and increasing the absorption rate by monolithic enteric capsule administration to humans of active ingredients compared to the bioavailability of active ingredients enterically coated for modified release or gastric protection, particularly acid sensitive active ingredients such as esomeprazole, omeprazole, and other proton pump inhibitors, systems for delivering active pharmaceutical ingredients to humans or animals via monolithic enteric capsules, and improved methods of treating gastrointestinal disorders with such methods and delivery systems.